Indian AI Platform iOncology.ai Showcased in BRICS Health Journal
iOncology.ai, an AI-driven cancer care platform from India, gains attention at the BRICS Summit, highlighting its potential in transforming cancer treatment in emerging economies.
An innovative artificial intelligence platform designed to enhance cancer care in India, iOncology.ai, has been prominently featured in the BRICS Health Journal during the recent BRICS Summit. The platform is a collaborative effort by the All India Institute of Medical Sciences (AIIMS), New Delhi, and the Centre for Development of Advanced Computing (C-DAC), Pune, with backing from the Ministry of Electronics and Information Technology.
AI-Driven Innovation for Cancer Care
The iOncology.ai platform aims to integrate cancer-related clinical data to assist in early detection, risk assessment, treatment planning, and comprehensive patient management. The technology is currently undergoing pilot-stage clinical validation to evaluate its efficacy in real-world clinical settings.
A review titled “Transforming cancer care in emerging economies: India’s AI innovation,” authored by Ashok Sharma and his team from AIIMS and C-DAC, examines the potential of AI in bolstering cancer screening and diagnosis. The review underscores the platform's ability to address disparities in cancer care, particularly across the Global South.
Addressing Global Cancer Care Disparities
Dr. Ashok Sharma highlighted the opportunity for India to showcase how locally developed solutions like iOncology.ai can bridge cancer-care gaps in resource-limited settings. The platform's development aligns with the goals of the BRICS countries, which collectively represent over 40% of the global population and face significant challenges in cancer diagnosis and treatment.
The review notes that BRICS nations report approximately 9 million new cancer cases and 4.66 million cancer-related deaths annually. There are marked differences in cancer patterns and access to medical care across these countries, making platforms like iOncology.ai crucial for improving outcomes.
Future Prospects and Clinical Validation
iOncology.ai is part of India's broader efforts to enhance cancer control through digital health initiatives, including population screening and the Ayushman Bharat Digital Mission. The platform employs Indian clinical, radiological, and histopathological datasets, with plans to include genetic data and integrate with electronic health-record systems.
Despite its promising potential, iOncology.ai is still in the research phase and lacks peer-reviewed evidence of its diagnostic accuracy and clinical utility. Comprehensive multicentre validation studies are essential before the platform can be widely adopted in clinical practice.